- Home
- ANAB vs NG Comparison
ANAB vs NG Comparison
Compare ANAB & NG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANAB | NG |
|---|---|---|
| Founded | 2005 | 1984 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANAB | NG |
|---|---|---|
| Price | $43.83 | $10.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $58.09 | $10.17 |
| AVG Volume (30 Days) | 431.3K | ★ 2.5M |
| Earning Date | 02-26-2026 | 01-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $169,467,000.00 | N/A |
| Revenue This Year | $135.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 196.42 | N/A |
| 52 Week Low | $12.21 | $2.26 |
| 52 Week High | $52.47 | $10.90 |
Technical Indicators
Market Signals| Indicator | ANAB | NG |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 58.18 |
| Support Level | $42.00 | $9.29 |
| Resistance Level | $47.36 | $10.10 |
| Average True Range (ATR) | 2.37 | 0.44 |
| MACD | -0.95 | -0.01 |
| Stochastic Oscillator | 19.77 | 78.91 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.